Saturn V Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Saturn V Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-500,551	Closed	-$4.69M	–	25
2025 Q2	$4.69M	Sell	500,551 -540,729	-52%	-$5.95M	1.9%	19
2025 Q1	$12.8M	Buy	1,041,280 +52,752	+5%	+$744K	6.46%	7
2024 Q4	$13.1M	Buy	988,528 +486,550	+97%	+$8.33M	5.12%	9
2024 Q3	$9.66M	Buy	501,978 +82,324	+20%	+$1.7M	3.45%	12
2024 Q2	$8.62M	Buy	419,654 +21,657	+5%	+$453K	3.26%	13
2024 Q1	$9.47M	Sell	397,997 -120,802	-23%	-$2.69M	3.8%	13
2023 Q4	$11.2M	Sell	518,799 -289,170	-36%	-$4.45M	4.29%	10
2023 Q3	$11.7M	Buy	807,969 +634,252	+365%	+$12M	4.91%	10
2023 Q2	$3.64M	Buy	+173,717	New	+$3.62M	2.02%	17

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Saturn V Capital Management's SNDX Position: Q3 2025 in Review

Saturn V Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 500,551 shares — an estimated $4.69M sold.

Saturn V Capital Management first reported a position in SNDX in Q2 2023 and held it in 9 quarters. The position peaked at $13.1M in Q4 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Saturn V Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Saturn V Capital Management sold 500,551 Syndax Pharmaceuticals shares in Q3 2025, an estimated $4.69M.
Saturn V Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2023 and held it in 9 quarters.
Saturn V Capital Management's Syndax Pharmaceuticals position peaked at $13.1M in Q4 2024.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.